Curated Wealth Partners
VRTX icon

Curated Wealth Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Curated Wealth Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$525K Buy
1,005
+566
+129% +$290K 0.04% 265
2026
Q2 		$218K Buy
+439
New +$195K 0.03% 225

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Curated Wealth Partners's VRTX Position: Q3 2026 in Review

Curated Wealth Partners increased its Vertex Pharmaceuticals (VRTX) stake by 129% in Q3 2026, buying an estimated $290K and bringing the position to 1,005 shares worth $525K. The position accounts for 0.04% of the portfolio, ranked #265.

Curated Wealth Partners first reported a position in VRTX in Q2 2026 and has held it in 2 quarters since. 1,556 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Curated Wealth Partners held 1,005 shares of Vertex Pharmaceuticals worth $525K as of Q3 2026.
  • Curated Wealth Partners bought 566 Vertex Pharmaceuticals shares in Q3 2026, an estimated $290K.
  • Vertex Pharmaceuticals made up 0.04% of Curated Wealth Partners's portfolio in Q3 2026, its #265 holding.
  • Curated Wealth Partners first reported a position in Vertex Pharmaceuticals in Q2 2026 and has held it in 2 quarters since.
  • 1,556 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Curated Wealth Partners's 13F filing for Q3 2026, filed 15 Oct 2026.